RxDoctor Payments Data

Robert Tilley, MD

Pulmonary Disease · Festus, MONPI 1962504886

Payments from drug & device makers

$1,613in general payments, 2019–2025

Across 39 payments — averaging $41.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$489
  • GSK$470
  • Inspire Medical Systems, Inc.$316
  • Jazz Pharmaceuticals Inc.$201
  • Philips North America LLC$40
  • Avadel CNS Pharmaceuticals, LLC$24
  • plus $73 from 4 others

What the payments were for

  • Consulting fees$1509%
  • Travel & lodging$48930%
  • Food & beverage$97560%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,613 in reported general payments places this provider in the 45th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$97,527
Medicare patients
571
Services billed
1,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate17$221,509
Trelegy ElliptaFluticasone/Umeclidin/Vilanter252$202,756
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr51$25,441
Spiriva RespimatTiotropium Bromide39$24,420
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$21,400
Incruse ElliptaUmeclidinium Bromide41$19,184
Breo ElliptaFluticasone/Vilanterol33$13,403
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$12,892
Spiriva HandihalerTiotropium Bromide19$12,620
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate32$7,041
Roflumilast46$4,505
Albuterol Sulfate HfaAlbuterol Sulfate164$3,846
ArexvyRsvpref3 Antigen/As01e/Pf15$3,793
Fluticasone Propionate HfaFluticasone Propionate12$3,418
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$2,670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Arexvy$470$264,577392 claims
AstraZenecaBreztri Aerosphere$16$21,40029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Festus

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →